Editas Medicine (EDIT) Reports Q3 Loss of $0.66
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Editas Medicine Announces Third Quarter 2019 Results and Update
November 12, 2019 7:02 AM ESTAmended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine
Appointed Judith R. Abrams, M.D., as Chief Medical Officer
EDIT-101 (AGN-151587) for LCA10 first patient dosing expected by early 2020
EDIT-301 for hemoglobinopathies in vivo pre-clinical data to be presented at ASH
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for... More
